Oct
2026
Fiera Milano, Italy
Visit us
stand 16F44, Finished Dosage & Formulation

Pharmidea

Exhibitor at CPHI Milan 2026
About Us

PHARMIDEA is EU GMP approved pharmaceutical manufacturer which provides services ranging from sterile drug development up to commercial production and supply worldwide. PHARMIDEA offers CDMO/ CMO services, R&D activities, EU-CTD, RA support, Out-licensing and product supply as well IMP services and interested in co-investment, co-development projects. 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Latvia
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
CMO/CDMO
Contract Service
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
Regulatory Affairs
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 16F44, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • Levosimendan

    Product Levosimendan

    Levosimendan indicated for short-term treatment of acutely decompensated severe chronic heart failure. Form & strength: 2.5mg/ml concentrate for solution for infusion 

  • Carbetocin

    Product Carbetocin

    Carbetocin indicated for the prevention of uterine atony following delivery of the infant by caesarean section under epidural or spinal anaesthesiaForm & strength: 100 mcg/ ml solution for injection
  • Caspofungin

    Product Caspofungin

    Caspofungin  powder for concentrate for solution for infusion
    50mg/vial
    70mg/vial
    Caspofungin is a new class of echinocandin antifungal agent with broad spectrum of activity used to treat a variety of fungal infections.

  • Atosiban

    Product Atosiban

    Atosiban indicated to delay imminent pre-term birth in pregnant adult women.Form & strength: 6.75 mg/ 0.9ml solution for injection and 37.5mg/ 5 ml concentrate for solution for infusion
  • Dexmedetomidine

    Product Dexmedetomidine

    Dexmedetomidine is indicated:1. for sedation of adult Intensive Care Unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation
    2. for sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. proc...